Russia, Ukraine and the Baltic states increasing in importance on the contract manufacturing market

11 December 2013

Russia seems to be an attractive country for pharmaceutical contract manufacturing, chiefly because of the strict regulations implemented in recent years which compel manufacturers to tap into production opportunities in the country.

On the other hand, a potential customer must exercise caution and check whether the internationally recognized Good Manufacturing Practice (GMP) rules are being observed by a production facility, according to the latest report from Poland-based market research group PMR, titled Pharmaceutical contract manufacturing and API sourcing 2013; Russia, Ukraine and the Baltic states.

GMP conversion process continues in Russia

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK